Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia

Abstract

These data demonstrate the potential for future studies of serum phosphoproteins as a readout of physiological function and might have utility in studies aimed at identification of biomarkers for drug response prediction or monitoring.

Complement pathway changes at age 12 are associated with psychotic experiences at age 18 in a longitudinal population-based study: evidence for a role of stress

“…We recently used discovery methods to compare the plasma proteome of age 12 subjects who developed psychotic disorder at age 18 and we found evidence implicating some protein members of the complement pathway at age 12 in subjects with PD at age 18 [27]. The complement system [28][29][30] has been implicated previously in schizophrenia and other major psychiatric disorders [31,32]. Complement has very well described roles in inflammation both peripherally and in the brain, roles in plasticity, neuronal growth, and neuroprotection are increasingly appreciated (for review see [33][34][35]).…”

Liquid‐phase based separation systems for depletion, prefractionation, and enrichment of proteins in biological fluids and matrices for in‐depth proteomics analysis—An update covering the period 2014–2016

“…Another study reported the use of IMAC for the enrichment of serum phosphoproteins in blood serum and label‐free LC–MS in expression mode (LC–MS E ) for protein identification . The serum with schizophrenia was taken from 23 patients before and after treatment with olanzapine.…”

Biomarkers and schizophrenia: a qualitative review

“…Most proteomic studies attempted to identify changes in protein levels, not considering the effects of post-translational modifications (PTMs). Nevertheless, characteristic changes in PTMs, such as phosphorylation, can be biologically informative [92]. Phosphorylation abnormalities in proteins involved in acute phase response and coagulation pathways were observed in serum from drug-naïve FEP patients compared to healthy controls [93].…”

“…Phosphorylation abnormalities in proteins involved in acute phase response and coagulation pathways were observed in serum from drug-naïve FEP patients compared to healthy controls [93]. More recently, another study was performed in order to investigate the effects of olanzapine on the serum phosphoproteome profile in FEP after 6-weeks treatment [92]. The main effects of olanzapine treatment were changes in the state of protein phosphorylation rather than in protein abundance [92].…”

“…More recently, another study was performed in order to investigate the effects of olanzapine on the serum phosphoproteome profile in FEP after 6-weeks treatment [92]. The main effects of olanzapine treatment were changes in the state of protein phosphorylation rather than in protein abundance [92]. Despite no information provided regarding the clinical response, it was suggested that antipsychotic drugs lead to downstream effects, which can be detected in the peripheral circulation, having utility as response biomarkers [92].…”